ABSTRACT
During Q4 2012 and Q1 2013, the cell therapy industry made strong progress in translation and commercialization. Continued development of the companies included in a dedicated stock market index suggests emergence of this industry as a distinct healthcare sector.
Subject(s)
Investments/economics , Stem Cell Research/economics , Stem Cell Transplantation/economics , HumansABSTRACT
During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3.
Subject(s)
Cell- and Tissue-Based Therapy/economics , Drug Industry/economics , Internationality , Clinical Trials as Topic/economics , Clinical Trials as Topic/legislation & jurisprudence , Commerce/economics , Drug Industry/legislation & jurisprudence , Humans , Legislation as Topic , Regenerative Medicine/economics , Regenerative Medicine/legislation & jurisprudence , Research Support as Topic/economics , United Kingdom , United States , United States Department of DefenseABSTRACT
In the first quarter of 2012, publicly traded companies in the cell-based therapy industry continued to show promising overall growth. Highlights included $85 million in new capital investment and steady clinical trial progress.
